Skip to content

Clinical study on safety and efficacy of Garcinia spp. product for body weight balance

Clinical study on safety and efficacy of Garcinia spp. product for body weight balance

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250707008
Enrollment
50
Registered
2025-07-07
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers with overweight or obesity (BMI greater than or equal 25 kg per m2) Garcinia pedunculata, Hydroxycitric acid (HCA), obesity, weight control, herbal medicine

Interventions

Consuming ready-to-eat jelly without Garcinia extract, 2 sachets/day (50 g/sachet) for 8 weeks,Consuming ready-to-eat jelly with Garcinia extract, 2 sachets/day (50 g/sachet) for 8 weeks
placebo ,Test product

Sponsors

Thailand Science Research and Innovation (TSRI)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Healthy female or male participants aged between 20-59 years 2. Able to listen, speak, and read the Thai language 3. Having a BMI greater than or equal to 25 kilograms per square meter 4. Willing to voluntarily participate in the research and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Have a history of allergy to Garcinia extract or any ingredients in the product, such as gelling agents, xylitol, or sorbitol 2. Have a history of taking medications that affect blood sugar or lipid levels 3. Have a history of taking weight control drugs or dietary supplements such as laxatives within the past two weeks 4. Have a history of taking any other Garcinia-containing products within the past two weeks 5. Have a history of hematologic disorders such as thrombocytopenia or abnormal bleeding 6. Diagnosed by a physician with diabetes ischemic heart disease heart failure or thyroid disorders 7. Having peptic ulcer disease or irritable bowel syndrome 8. Liver function test results showing aspartate aminotransferase or alanine aminotransferase more than 2 times the upper limit of normal 9. Kidney function test showing creatinine levels more than 1.5 times the upper limit of normal 10. Abnormal urine or stool test results 11. Diagnosed by a physician with severe psychiatric disorders 12. Have a history of receiving obesity treatment within the past three months 13. Currently pregnant or breastfeeding 14. Have a history of undergoing major surgery within the past 1 year

Design outcomes

Primary

MeasureTime frame
Body mass index Week 0, 4, 8 Body weight and height measured using digital scale and stadiometer,Body weight Week 0, 4, 8 measured using digital scale and stadiometer

Secondary

MeasureTime frame
Body fat percentage Week 0, 4, 8 Bioelectrical impedance analysis,Waist circumference Week 0, 4, 8 Measured using flexible non-stretchable tape,Lipid profiles Week 0, 4, 8 Enzymatic colorimetric method,Serum leptin concentration Week 0, 4, 8 Measured using ELISA assay,Participant satisfaction Week8 Questionnaire-based evaluation

Countries

Thailand

Contacts

Public ContactKrongkarn Choothip

Faculty of Medical Science, Naresuan University, Phitsanulok

krongkarnc@nu.ac.th0817853618

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026